Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 as Adjunctive Therapy in Focal-onset Epilepsy (with Open-label Extension)
DRKS00026803Phase 2Active, not recruiting
- Sponsor
- Xenon Pharmaceuticals
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of azetukalner in Focal Onset Epilepsy (5 arms), sponsored by Xenon Pharmaceuticals. Started Mar 2022; status: active, not recruiting.
02
Drugs
azetukalner
03
Conditions
Focal Onset Epilepsy
Beyond the preview
Go deeper on DRKS00026803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00026803.